Clinical Trial Update: Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy for Neuroblastoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating defibrotide prophylaxis to prevent transplant-associated thrombotic microangiopathy in neuroblastoma patients has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma
• Transplant-associated Thrombotic Microangiopathy

Drugs mentioned

• Defibrotide (defibrotide)

Snippet

Sponsor: University of California, San Francisco | Conditions: Transplant-Associated Thrombotic Microangiopathy, Neuroblastoma | Phase 2 | Status: WITHDRAWN